Condition: Multiple Myeloma Refractory · Multiple Myeloma in Relapse · Sponsor: CellCentric Ltd.
The purpose of this study is to learn more about the anti-cancer activity of inobrodib, when given in combination with pomalidomide and dexamethasone, in patients with multiple myeloma that has come back following treatment and which no longer responds to available therapies. The study treatment will not be compared to any other treatment and patients will know what treatment they are receiving. This study will also further explore the side effects of inobrodib in combination with these other medicines.
This description comes directly from the study's public registry record.
CCS1477-04 Clinical Operations · +44 1799 531130 · DOMMINO-1@cellcentric.com
Always discuss trial participation with your own doctor first.
| University of California, San Francisco | San Francisco, California, United States | Recruiting |
| H Lee Moffitt Cancer Center & Research Institute | Tampa, Florida, United States | Recruiting |
| Winship Cancer Institute | Atlanta, Georgia, United States | Recruiting |
| American Oncology Partners, PA | Bethesda, Maryland, United States | Recruiting |
| Washington University School of Medicine | St Louis, Missouri, United States | Recruiting |
| University of Nebraska Medical Center | Omaha, Nebraska, United States | Recruiting |
| Rutgers Cancer Institute of New Jersey | New Brunswick, New Jersey, United States | Recruiting |
| Levine Cancer Institute | Charlotte, North Carolina, United States | Recruiting |
| Wake Forest University Health Sciences | Winston-Salem, North Carolina, United States | Recruiting |
| Cleveland Clinic | Cleveland, Ohio, United States | Recruiting |
| University of Pennsylvania, Abramson Cancer Center | Philadelphia, Pennsylvania, United States | Recruiting |
| Fred Hutchinson Cancer Center | Seattle, Washington, United States | Recruiting |
+ 8 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07096778